Tau-pathology occurs downstream of Aβ accumulation in Alzheimer’s disease.59–61 The ablation or reduction of endogenous, nonaggregated WT tau prevents or diminishes Aβ toxicity in vitro and in vivo. This evidence concerns the gene MAPT and Alzheimer disease.